Fluicell AB Asset Resilience Ratio
Fluicell AB asset resilience ratio. Fluicell AB (FLUI) has an Asset Resilience Ratio of 12.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Fluicell AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Fluicell AB (2016–2025)
Asset resilience ratio of Fluicell AB from 2016 to 2025. This chart shows how Fluicell AB's Asset Resilience Ratio has changed over time. Read FLUI total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Fluicell AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Fluicell AB assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr2.26 Million | 12.24% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr2.26 Million | 12.24% |
Asset Resilience Insights
- Moderate Liquidity: Fluicell AB has 12.24% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Fluicell AB Industry Peers by Asset Resilience Ratio
Compare Fluicell AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Fluicell AB Asset Resilience Ratio by Year (2016–2025)
Fluicell AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Fluicell AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.24% | Skr2.26 Million ≈ $243.43K |
Skr18.48 Million ≈ $1.99 Million |
-50.18pp |
| 2024-12-31 | 62.43% | Skr15.92 Million ≈ $1.71 Million |
Skr25.51 Million ≈ $2.75 Million |
+32.85pp |
| 2023-12-31 | 29.58% | Skr2.76 Million ≈ $297.34K |
Skr9.34 Million ≈ $1.01 Million |
-47.41pp |
| 2022-12-31 | 76.99% | Skr24.46 Million ≈ $2.63 Million |
Skr31.77 Million ≈ $3.42 Million |
+0.29pp |
| 2021-12-31 | 76.70% | Skr20.69 Million ≈ $2.23 Million |
Skr26.98 Million ≈ $2.90 Million |
+0.98pp |
| 2020-12-31 | 75.71% | Skr18.80 Million ≈ $2.02 Million |
Skr24.83 Million ≈ $2.67 Million |
+33.40pp |
| 2019-12-31 | 42.32% | Skr8.44 Million ≈ $907.96K |
Skr19.94 Million ≈ $2.15 Million |
-43.27pp |
| 2018-12-31 | 85.59% | Skr22.23 Million ≈ $2.39 Million |
Skr25.97 Million ≈ $2.80 Million |
+17.69pp |
| 2017-12-31 | 67.91% | Skr7.83 Million ≈ $842.96K |
Skr11.54 Million ≈ $1.24 Million |
+28.30pp |
| 2016-12-31 | 39.60% | Skr1.10 Million ≈ $118.27K |
Skr2.77 Million ≈ $298.63K |
-- |
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more